CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing. Proceeds from the financing will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS). ELI-002 targets all seven KRAS mutations that drive 99% of all mKRAS-driven cancers, estimated to be 25% of all human solid tumors.
“We believe ELI-002 can become a universal mKRAS vaccine with the potential to treat and prevent disease recurrence for hundreds of thousands of patients with mKRAS-driven cancers, including pancreatic, colorectal and lung cancer,” said Robert Connelly, CEO of Elicio. “This new funding is a strong endorsement of this program, the Amphiphile platform, and our progress.”
Elicio has established an international investor base, including Clal Biotechnology Industries, Livzon Pharmaceutical Group and Efung Capital. “We are gratified to be able to expand our investor base and strengthen our balance sheet as we advance multiple Amphiphile immuno-therapies towards initial patient studies,” Connelly said.
Elicio’s AMP KRAS vaccine ELI-002 has completed preclinical validation, IND-enabling GLP toxicology studies, GMP manufacturing, and a pre-IND meeting with the FDA and Elicio intends to begin an initial patient study in pancreatic cancer patients in the first half of 2020. These trials will be multi-site, randomized, controlled studies. Initial ELI-002 pancreatic cancer patient data is expected in the second half of 2020.
About the Amphiphile Platform
The Elicio Amphiphile platform enables precise targeting and delivery of immunogens and cell-therapy activators directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, defeat solid and hematologic cancers, and prevent their recurrence. Once in the lymph nodes, Amphiphile immunotherapies are taken up by antigen presenting cells (APC’s) to orchestrate signaling to natural or engineered immune cells in order to maximize therapeutic immune responses to disease. This strategy has been used to improve the activity of immunostimulatory agents, antigens, adjuvants, and cell-therapies that generate little to no response when used in the conventional forms. By precisely targeting these immunotherapies to the lymph nodes, Amphiphiles can unlock their full potential to generate and amplify anti-tumor immune responses. This substantially enhanced anti-tumor functionality and long-term protective memory may someday unlock the full potential of the immune response to eliminate cancer.
About Elicio Therapeutics
Elicio Therapeutics, based in Cambridge MA, is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers. Elicio’s lead Amphiphile vaccine targeting KRAS-driven cancers will begin initial patient studies in pancreatic and colorectal cancer patients in the first half of 2020. These programs are followed by a broad preclinical pipeline of lymph node targeted immunotherapies. For more information please visit https://elicio.com/.